Inhibition of cardiac ATP-dependent potassium channels by sulfonylurea drugs.
Gögelein
H
H
Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Frankfurt/Main, Germany. heinz.goegelein@aventis.com
D000255:Adenosine Triphosphate / Q000494:pharmacology*; D000818:Animals; D001549:Benzamides / Q000494:pharmacology; D006321:Heart / Q000187:drug effects*; D006801:Humans; D026902:Potassium Channel Blockers; D015221:Potassium Channels / Q000032:analysis; D013453:Sulfonylurea Compounds / Q000494:pharmacology*
D001549:Benzamides; D026902:Potassium Channel Blockers; D015221:Potassium Channels; D013453:Sulfonylurea Compounds; D000255:Adenosine Triphosphate; C410297:HMR 1098